202 related articles for article (PubMed ID: 3878482)
1. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
[TBL] [Abstract][Full Text] [Related]
2. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
Schneider JS; Yuwiler A; Markham CH
Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
[TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
German DC; Dubach M; Askari S; Speciale SG; Bowden DM
Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295
[TBL] [Abstract][Full Text] [Related]
4. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
[TBL] [Abstract][Full Text] [Related]
5. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
7. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
10. MPTP-induced ventral mesencephalic cell loss in the cat.
Williams JL; Schneider JS
Neurosci Lett; 1989 Jul; 101(3):258-62. PubMed ID: 2570385
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
Brain Res; 1990 Apr; 513(2):320-4. PubMed ID: 2350702
[TBL] [Abstract][Full Text] [Related]
12. Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys.
Ohye T; Ichinose H; Ogawa M; Yoshida M; Nagatsu T
Neurodegeneration; 1995 Mar; 4(1):81-5. PubMed ID: 7600187
[TBL] [Abstract][Full Text] [Related]
13. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
[TBL] [Abstract][Full Text] [Related]
14. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.
Gupta M; Gupta BK; Thomas R; Bruemmer V; Sladek JR; Felten DL
Neurosci Lett; 1986 Oct; 70(3):326-31. PubMed ID: 3490639
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry.
Schneider JS; Markham CH
Brain Res; 1986 May; 373(1-2):258-67. PubMed ID: 2872936
[TBL] [Abstract][Full Text] [Related]
16. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
[TBL] [Abstract][Full Text] [Related]
17. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.
Schneider JS; Yuwiler A; Markham CH
Exp Neurol; 1986 Feb; 91(2):293-307. PubMed ID: 3484707
[TBL] [Abstract][Full Text] [Related]
18. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.
Markey SP; Johannessen JN; Chiueh CC; Burns RS; Herkenham MA
Nature; 1984 Oct 4-10; 311(5985):464-7. PubMed ID: 6332988
[TBL] [Abstract][Full Text] [Related]
19. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Schultz W; Scarnati E; Sundström E; Tsutsumi T; Jonsson G
Exp Brain Res; 1986; 63(1):216-20. PubMed ID: 3488228
[TBL] [Abstract][Full Text] [Related]
20. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR
Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
